Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This policy brief reports that post-drug syndromes like Post-Finasteride Syndrome are largely overlooked in current pharmacovigilance systems, which prioritize acute drug reactions, resulting in inadequate recognition and management of persistent medication-induced conditions.

This review proposes focusing on relationships between neuroactive steroids and psychiatric disorder symptoms, rather than relying on traditional disorder classifications, and reports no new clinical findings.

This study identified significant trends in interest around selective androgen receptor modulators, with increasing attention contrasting stagnant or declining interest in post-cycle therapies and anabolic steroids, and calls for clinicians to use social and prescription data to adjust treatment protocols accordingly.

This review examines alopecia as a side effect of psychotropic medications, noting that it is typically reversible after stopping the drug, but it reports no new results.

This chapter reviews various chemical synthesis methods for pharmaceutical compounds and reports no new experimental results.

This article provides contact details and affiliations for Amy M. Karch and Fred E. Karch; it presents no new research findings.

This correction clarifies the affiliations of researcher D. Piomelli in a case report on symptom improvement in a chronic psychotic patient treated with finasteride, without presenting new research findings.

In this study, researchers explored drug repurposing as a potential strategy for treating psoriasis and identified Pioglitazone, Trimipramine, and Dimetindene as promising candidates for this indication, based on molecular docking and predictive algorithms.

This review discusses cutaneous adverse effects of psychotropic medications and reports no new findings, emphasizing the importance of psychiatrists being aware of these potential skin reactions.

This study outlines the potential of drug repurposing to discover new uses for existing medications, emphasizing its cost-effectiveness, efficiency, and ability to address rare diseases by targeting novel biological mechanisms and relying on established safety profiles.

This review discusses the role of neuro(active)steroids, particularly those in the 5α reductase pathway, in modulating dopamine signaling and their impact on neuropsychiatric disorders characterized by dopamine imbalances, including addiction, schizophrenia, and Parkinson's Disease.

This review discusses the off-label use of SSRIs to manage inappropriate sexual behavior in elderly dementia patients and highlights the unclear risk of post-SSRI sexual dysfunction, noting a need for high-quality clinical trials.

This study reviewed 16 notable drug repurposing patent applications from 2025, highlighting potential new uses such as guanfacine for autonomic dysfunction and disulfiram for subarachnoid hemorrhage survival, though many disclosures lack peer-reviewed studies and no patents are granted.

In this report, the European Medicines Agency confirmed in 2025 that finasteride, a drug used to treat hair loss in men, is linked to suicidal thoughts, a concern previously raised by patient advocacy groups.

This source reviews various perspectives from marketing and business literature to help pharmacists better define and communicate their "product," which can include tangible or intangible offerings, in efforts to satisfy medication-related needs and enhance patient health outcomes.

This article reviews the interconnectedness of the skin and nervous system and discusses various treatment options for psychophysiological skin disorders, reporting no new clinical results.

This article discusses the growing public health concerns associated with the surge in online sales of prescription-only medicines, highlighting the need for regulatory action and public education to address potential risks.

This study found that in sleep-deprived rats, increased 5α-reductase expression and activity in the prefrontal cortex contributed to psychosis- and mania-like symptoms, which finasteride ameliorated in a dose-dependent manner.

The MHRA announced on 11 May 2026 that it will update the product information for finasteride and dutasteride to include more details on potential psychiatric and sexual side effects, following a review of existing evidence.

This chapter reviews secondary uses for various drugs, noting that some have regulatory approval, indicating verified safety and efficacy, while others lack approval despite strong evidence.

This review discusses the early stages of pharmaceutical product promotion on the internet and highlights the current lack of specific regulatory guidance for such advertising.

This review describes psychotropic drug-related hair loss as a possible but uncommon side effect, with resolution typically achieved by discontinuing the medication, and emphasizes clinician-patient discussions for managing the condition.

This review introduces pharmacophore technology and discusses its applications in toxicity prediction and limits, but reports no new clinical results.

This study reviewed the dosages of products approved in Japan from 2003-2010 and found that 28.1% were at different levels than in the U.S., with limited evidence suggesting different clinical responses.

This study found that duloxetine and escitalopram exhibited broad-spectrum antimicrobial activity, while buspirone had selective effects, and finasteride disrupted yeast virulence traits, suggesting these drugs could be repurposed as antimicrobial therapies.